Evidence map›Paper›PMID 16875837›Full record

ArticleJournal of the American Society for Mass Spectrometry2006

The antigenic determinants on HIV p24 for CD4+ T cell inhibiting antibodies as determined by limited proteolysis, chemical modification, and mass spectrometry.

Jason G Williams, Kenneth B Tomer, Catarina E Hioe, Susan Zolla-Pazner, Philip J Norris

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of the American Society for Mass Spectrometry, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jason G WilliamsNational Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Laboratory of Structural Biology, 111 TW Alexander Drive, MD F0-03, 27709, Research Triangle Park, NC, USA.
Kenneth B TomerNational Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Laboratory of Structural Biology, 111 TW Alexander Drive, MD F0-03, 27709, Research Triangle Park, NC, USA. tomer@niehs.nih.gov.
Catarina E HioeNew York Veterans Affairs Medical Center and Department of Pathology, New York University School of Medicine, New York, New York, USA.
Susan Zolla-PaznerNew York Veterans Affairs Medical Center and Department of Pathology, New York University School of Medicine, New York, New York, USA.
Philip J NorrisBlood Systems Research Institute and Departments of Laboratory Medicine and Medicine, University of California-San Francisco, San Francisco, California, USA.
National Institutes of Health · USNew York University · USUniversity of California, San Francisco · US

Funding

Why Th Cells from HIV+ Don't Respond to HIV AntigensR01AI048371 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HIOE, CATARINA E · 2002 to 2010
$2.6M
CHARACTERIZATION OF HIV-1-SPECIFIC T HELPER CELL CLONESK08AI001698 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI NORRIS, PHILIP J · 2000 to 2004
$598k
STRUCTURAL STUDIES OF HIV PROTEINSZ01ES050150 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI TOMER, KENNETH · 1996 to 2008
$249k
Intramural NIH HHSNIAID NIH HHS AI-48371NIAID NIH HHS K08 AI001698
6 · The paper itself

Abstract

In the last decade, mass spectrometry has been employed by more and more researchers for identifying the proteins in a macromolecular complex as well as for defining the surfaces of their binding interfaces. This characterization of protein-protein interfaces usually involves at least one of several different methodologies in addition to the actual mass spectrometry. For example, limited proteolysis is often used as a first step in defining regions of a protein that are protected from proteolysis when the protein of interest is part of a macromolecular complex. Other techniques used in conjunction with mass spectrometry for determining regions of a protein involved in protein-protein interactions include chemical modification, such as covalent cross-linking, acetylation of lysines, hydrogen-deuterium exchange, or other forms of modification. In this report, both limited proteolysis and chemical modification were combined with several mass spectrometric techniques in efforts to define the protein surface on the HIV core protein, p24, recognized by two different monoclonal human antibodies that were isolated from HIV+ patients. One of these antibodies, 1571, strongly inhibits the CD4+ T cell proliferative response to a known epitope (PEVIPMFSALSEGATP), while the other antibody, 241-D, does not inhibit as strongly. The epitopes for both of these antibodies were determined to be discontinuous and localized to the N-terminus of p24. Interestingly, the epitope recognized by the strongly inhibiting antibody, 1571, completely overlaps the T cell epitope PEVIPMFSALSEGATP, while the antibody 241-D binds to a region adjacent to the region of p24 recognized by the antibody 1571. These results suggest that, possibly due to epitope competition, antibodies produced during HIV infection can negatively affect CD4+ T cell-mediated immunity against the virus.

Indexed as

EpitopesSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAmino Acid SequenceAntibodies, BlockingAntibodies, MonoclonalCD4-Positive T-LymphocytesHIV Core Protein p24HumansMolecular Sequence DataProtein ConformationAntibodies, BlockingAntibodies, MonoclonalEpitopesHIV Core Protein p24

Identifiers

PMID16875837
OpenAlexW2007290517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.